| COVID-19 prophylaxis (excluding children) | |
| Immunostimulants drugs | |
| neutralizing antibody | |
| bamlanivimab monotherapy | BLAZE-2 US ... |
| casirivimab/imdevimab (Ronapreve) | Cov-2069 ... |
| cilgavimab and tixagevimab (Evusheld) | Jurdi PROVENT |
| 5405 | Ahn, 2020 | 2 | 0 | 0 | excluded | risk of bias not avaialble | |
| 5408 | Shen, 2020 | 2 | 0 | 0 | excluded | risk of bias not avaialble | |
| 5409 | Ye, 2020 | 2 | 0 | 0 | excluded | risk of bias not avaialble | |
| 5410 | Zhang, 2020 | 2 | 0 | 0 | excluded | risk of bias not avaialble | |
| 5411 | Zhang, 2020 | 2 | 0 | 0 | excluded | risk of bias not avaialble | |
| 5569 | Dai W, 2020 | 2 | 13 | 4 | excluded | not a RCT | high risk of bias |
| 10178 | Bargay-Lleonart, 2022 | 2 | 1 | 0 | excluded | risk of bias not avaialble |
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
